oncology
Breast Cancer

Recurrence score guides chemo use

Up to 85% of women with early ER-positive, HER2-negative, node-negative breast cancer can be spared chemotherapy, according to results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The TAILORx trial of more than 10,000 women found endocrine therapy alone was non-inferior to endocrine therapy plus chemotherapy in women with a midrange ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic